ELAN in the 13F filings
Elanco Animal Health Inc · CUSIP 28414H103
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 14 Nov 2023
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 12 listed it in both
- Shares listed
- 149,614,660
- combined, among listed positions
- Reported value
- $1.7bn
- combined, at the quarter end
Managers listing ELAN in Q3 2023
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Woodline Partners LPexisting position · 3,840,127 shares now+3,130,273
- T. Rowe Price Associates Incexisting position · 19,921,006 shares now+2,494,084
- Holocene Advisors LPexisting position · 6,716,650 shares now+1,746,654
- Citadel Advisors LLCexisting position · 13,815,603 shares now+559,193
- Davidson Kempner Capital Management LPexisting position · 642,508 shares now+490,408
Reductions
- Balyasny Asset Management LLCexisting position · 3,815,986 shares now-7,337,464
- D. E. Shaw & Co.existing position · 5,090,661 shares now-4,423,987
- Rokos Capital Management LLPexisting position · 5,331,405 shares now-833,787
- Man Group PLCexisting position · 2,322,953 shares now-436,165
- Dodge & Coxexisting position · 84,203,300 shares now-418,050
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2018 | 13 | $388m | n.a. | n.a. |
| Q4 2018 | 7 | $383m | n.a. | n.a. |
| Q1 2019 | 14 | $3.5bn | n.a. | n.a. |
| Q2 2019 | 10 | $3.7bn | n.a. | n.a. |
| Q3 2019 | 13 | $2.9bn | n.a. | n.a. |
| Q4 2019 | 13 | $3.3bn | n.a. | n.a. |
| Q1 2020 | 13 | $2.9bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.4bn | n.a. | n.a. |
| Q3 2020 | 6 | $2.9bn | n.a. | n.a. |
| Q4 2020 | 16 | $4.1bn | n.a. | n.a. |
| Q1 2021 | 12 | $4.0bn | n.a. | n.a. |
| Q2 2021 | 14 | $4.6bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.0bn | n.a. | n.a. |
| Q4 2021 | 13 | $3.8bn | n.a. | n.a. |
| Q1 2022 | 11 | $3.1bn | n.a. | n.a. |
| Q2 2022 | 11 | $2.4bn | n.a. | n.a. |
| Q3 2022 | 15 | $1.9bn | n.a. | n.a. |
| Q4 2022 | 15 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2023 | 13 | $1.6bn | n.a. | n.a. |
| Q3 2023 | 12 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 9 | $1.9bn | 2 | 9 |
| Q1 2024 | 10 | $2.3bn | 7 | 3 |
| Q2 2024 | 9 | $2.1bn | 6 | 4 |
| Q3 2024 | 7 | $1.5bn | 4 | 3 |
| Q4 2024 | 5 | $1.5bn | 2 | 2 |
| Q1 2025 | 6 | $1.5bn | 4 | 1 |
| Q2 2025 | 9 | $2.5bn | 8 | 2 |
| Q3 2025 | 12 | $3.4bn | 7 | 5 |
| Q4 2025 | 9 | $3.3bn | 17 | 15 |
| Q1 2026 | 5 | $3.0bn | 15 | 16 |
| Q2 2026 | 10 | $3.6bn | 15 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ELAN and LLY →ELAN and JNJ →ELAN and VRTX →Choose a stock to compare with ELAN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ELAN, latest filings →Back to the 13F Explorer →